公开(公告)号：EP1520587A1

公开(公告)日：2005-04-06

申请号：EP03724819.2

申请日：2003-05-08

申请人： Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros ,  Centro Nacional de Biopreparados

发明人： Lastre Gonzalez, Miriam de San Juan ,  Perez Martin, Oliver Germán ,  Labrada Rosado, Alexis ,  Bidot Martinez, Igor ,  Perez Lastre, Jorge Ernesto ,  Bracho Granada, Gustavo Rafael ,  Del Campo Alonso, Judith Monica ,  Perez Lastre, Dainerys Aleida ,  Facenda Ramos, Elisa ,  Zayas Vignier, Caridad ,  Rodriguez Martinez, Claudio ,  Sierra Gonzélez, Victoriano Gustavo

IPC分类号： A61K39/39 ,  A61K39/35

CPC分类号： A61K39/35 ,  A61K2039/55505 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/57 ,  A61K2039/6018

摘要： The present invention rebates to the field of Immunology, specifically with the branch of Immuno-Allergy and in particular with the use of adjuvant or carrier compounds, capable of modulating the immune response to allergens. The technical objective that is pursued is to obtain a pharmaceutical preparation of therapeutic or prophylactic use using bacterial proteoliposomes, which transform the allergic response Th2 and IgE when being applied in allergic individuals, toward a protector response Th1; as well as it is able to prevent the appearance and the development of allergies in individuals non-allergic yet. The vaccine composition consists of proteoliposomes derived from Gram-negative bacteria coupled to allergens and optionally contains other adjuvants or antigens. The method for its preparation and an immunization scheme of two doses are provided.

摘要翻译： 本发明回扣免疫学领域，特别是与免疫过敏分支，特别是与使用的辅助剂或载体的化合物，能够调节对变应原的免疫应答。 该技术目标是追求所做的是使用细菌的脂蛋白体，其中变换当被施加在过敏性个体价值，朝向Th1应答保护变应性Th2应答和IgE，以获得治疗或预防用途的药物制剂; 以及它能够防止出现过敏的个人价值不过敏的发展呢。 疫苗组合物从耦合到过敏原的革兰氏阴性细菌衍生的脂蛋白体besteht并任选含有其它佐剂或抗原。 提供了用于其制备方法和两种剂量的免疫方案的方法。